Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Yongsu Zhen"'
Publikováno v:
Drug Delivery, Vol 29, Iss 1, Pp 1243-1256 (2022)
The present study aimed to evaluate the anti-tumor efficacy of the epidermal growth factor receptor (EGFR)-targeting recombinant fusion protein Fv-LDP-D3 and its antibody-drug conjugate Fv-LDP-D3-AE against esophageal cancer. Fv-LDP-D3, consisting of
Externí odkaz:
https://doaj.org/article/97c8b2f091ba4c18afabd578bf2af9e7
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 11, Pp 3379-3392 (2021)
Esophageal cancer (EC) is one of the most common cancers with high morbidity and mortality rates. EC includes two histological subtypes, namely esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC primarily occurs in Ea
Externí odkaz:
https://doaj.org/article/9eca37b54fe44c4b85dd7c58d9a19ab3
Publikováno v:
Molecular Oncology, Vol 12, Iss 3, Pp 339-355 (2018)
CD30 is a 120‐kDa type I transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large‐cell lymphoma (ALCL). CD30‐targeted treatm
Externí odkaz:
https://doaj.org/article/a5e9f40a4fe34d76bda22e92c893983f
Autor:
Dongmei Fan, Linlin Jiang, Yuewen Song, Shiqi Bao, Yuanyuan Yang, Xiangfei Yuan, Yongsu Zhen, Ming Yang, Dongsheng Xiong
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
The 5-year survival rate of patients with B cell lymphoma is about 50% after initial diagnosis, mainly because of resistance to chemotherapy. Hence, it is necessary to understand the mechanism of chemo-resistance and to explore novel methods to circu
Externí odkaz:
https://doaj.org/article/9c88ae9e6f2a4ae98f86e934fd84aee9
Autor:
Jianhua Gong, Yanbo Zheng, Ying Wang, Weijin Sheng, Yi Li, Xiujun Liu, Shuyi Si, Rongguang Shao, Yongsu Zhen
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0191984 (2018)
Through cell-based screening models, we have identified a new compound IMB5043, a thiophenylated pyridazinone, which exerted cytotoxicity against cancer cells. In the present study, we evaluated its antitumor efficacy and the possible mechanism. By M
Externí odkaz:
https://doaj.org/article/36710e6d2df94d3198bc0047d29d345d
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 5, Iss 3, Pp 264-269 (2015)
In this study, N-terminal site-specific mono-PEGylation of the recombinant lidamycin apoprotein (rLDP) of lidamycin (LDM) was prepared using a polyethyleneglycol (PEG) derivative (Mw 20 kDa) through a reactive terminal aldehyde group under weak acidi
Externí odkaz:
https://doaj.org/article/39ac1293de724c2baad254e065dd67cb
Publikováno v:
Biochemical pharmacology. 197
Mithramycin A (MIT) has reacquired extensive research attention due to its anti-solid tumor activity and improved pharmacological production. Mechanismly, MIT was broadly used as a c-Myc inhibitor, and c-Myc regulated CD47 and PD-L1 expression which
Autor:
Dongsheng Xiong, Linlin Jiang, Yuanyuan Yang, Yuewen Song, Dongmei Fan, Ming Yang, Shiqi Bao, Yongsu Zhen, Xiangfei Yuan
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Frontiers in Oncology
Frontiers in Oncology
The 5-year survival rate of patients with B cell lymphoma is about 50% after initial diagnosis, mainly because of resistance to chemotherapy. Hence, it is necessary to understand the mechanism of chemo-resistance and to explore novel methods to circu
Autor:
Qing Lin, Xiangbin Wang, Hua-Liang Huang, Changcheng Yin, Yongsu Zhen, Mengyuan Liu, Zhong Zhang
Publikováno v:
Biochemical Journal. 406:237-246
Anti-TNF-alpha [anti-(tumour necrosis factor-alpha)] therapy is widely considered to be among the most efficient treatments available for rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease. In the present study a tetravalent min
Autor:
Li Ma, Ming Yang, Xiao-yun Zhang, Yongsu Zhen, Linlin Jiang, Shiqi Bao, Dongmei Fan, Yuan Zhou, Dongsheng Xiong
Publikováno v:
Journal of drug targeting. 24(1)
Rituximab is widely used in clinical setting for the treatment of B malignant lymphoma and has achieved remarkable success. However, in most patients, the disease ultimately relapses and become resistant to rituximab. To overcome the limitation, ther